1. Germany Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
MERCK Kommanditgesellschaft auf Aktien

MERCK Kommanditgesellschaft auf Aktien

MER.SW
MERCK Kommanditgesellschaft auf AktienCH flagSwiss Exchange
125.25
CHF
-2.25
- -
54.46BMarket Cap
MERCK Kommanditgesellschaft auf Aktien
MER.SW
(Swiss Exchange)

Recent

price

125.25

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
23.64
25.73
25.56
26.12
29.49
34.59
33.38
- -
- -
- -
- -
- -
48.28
48.66
48.54
48.21
Revenue per Share
- -
1.4
1.3
2.77
2.66
2.56
3.75
5.99
- -
- -
- -
- -
- -
6.5
6.39
6
5.82
Basic EPS, GAAP
- -
1.9
4.6
3.94
4.78
3.45
3.84
3.18
- -
- -
- -
- -
- -
4.05
5.52
4.54
5.1
Free Cash Flow per Basic Share
- -
0.2
0.98
0.95
1.16
1.29
1.37
1.43
- -
- -
- -
- -
- -
0.65
0.65
0.65
0.69
Dividend per Share
- -
1.3
1.3
1.3
1.3
1.3
1.3
1.3
- -
- -
- -
- -
- -
47.82
52.1
56.59
58.11
Book Value per Share
- -
-2.92
-1.22
2.77
0.93
-28.85
-25.2
-18.02
- -
- -
- -
- -
- -
5.42
10.42
7.05
8.68
Tangible Book Value per Share
- -
435
434
434
435
436
434
435
- -
- -
- -
- -
- -
435
435
435
435
Basic Weighted Avg Shares
9,291
10,276
11,173
11,095
11,363
12,845
15,024
14,517
14,836
16,152
17,534
19,687
22,232
20,993
21,156
21,102
20,956
Sales/Revenue/Turnover
11.9
11.98
16.93
18.83
15.39
16.88
15.45
15.23
12.36
14.26
16.03
21.38
21.37
17.02
18.95
17.33
17.15
Operating Margin (%)
1,258
1,597
1,397
1,458
1,361
1,511
1,934
1,758
1,812
1,944
1,938
1,767
2,030
1,880
2,134
2,298
2,322
Depreciation Expense
642
606
567
1,202
1,157
1,115
1,629
2,605
3,374
1,320
1,987
3,055
3,326
2,824
2,777
2,608
2,532
Net Income, GAAP
25.5
26.32
18.34
12.93
25.19
24.75
24.19
- -
25.19
25.36
24.22
21.89
22.11
18.66
21.24
20.95
20.99
Effective Tax Rate (%)
6.9
5.9
5.07
10.84
10.18
8.68
10.84
17.94
22.74
8.17
11.33
15.52
14.96
13.45
13.13
12.36
12.08
Profit Margin (%)
2,306
2,037
2,064
3,486
3,879
-2,040
-1,419
-1,180
719
-2,839
49
550
2,687
3,694
2,155
4,188
4,813
Working Capital
5,127
3,989
3,362
3,258
3,444
9,513
8,705
7,946
6,681
8,587
9,745
8,270
9,200
9,239
6,998
10,731
10,802
LT Debt
10,377
10,494
10,415
11,069
11,801
12,855
14,050
14,066
17,233
17,914
17,017
21,416
26,005
26,755
29,989
28,660
29,819
Total Equity
6.33
5.61
9.88
11.99
7.85
7.17
6.47
- -
5.2
5.74
6.73
10.19
10.29
7.62
7.88
6.86
6.79
Return on Invested Capital (%)
18.84
13.81
14.55
30.08
25.26
13.5
13.83
- -
22.45
7.28
9.04
12.63
12.47
10.21
9.41
8.35
8.16
Return on Capital (%)
113.5
107.31
100.27
212.7
204.76
197.31
288.32
461.06
54.76
11.09
15.9
21.33
19.16
14.18
12.78
11.04
10.38
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1,651
1,221
1,236
LT Borrowings
- -
10,206
- -
LT Finance Leases
- -
525
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
435
435
435
Market Capitalization
- -
- -
45,507

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
12,876
13,230
14,162
Cash, Cash Equivalents & STI
2,924
2,925
3,774
Accounts Receivable, Net
4,222
3,947
4,318
Inventories
4,510
4,562
4,782
Total Current Liabilities
8,637
9,042
9,349
Payables & Accruals
- -
- -
- -
ST Debt
1,651
1,221
1,236
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.87%
11.56%
-4.43%
Free Cash Flow
7.19%
6.82%
-17.82%
Net Income, GAAP
16.5%
7.96%
-6.09%
Sales/Revenue/Turnover
5.34%
4.03%
-0.26%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,120
5,352
5,266
5,418
21,156
2025
5,280
5,255
5,318
5,249
21,102
2026
5,134
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.6
1.4
1.86
- -
6.39
2025
1.69
1.5
2.07
- -
6
2026
1.52
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.12
0.65
- -
- -
0.65
2025
0.11
0.65
- -
- -
0.65
2026
0.03
- -
- -
- -
- -
Similar Companies
Tauriga Sciences, Inc. (TAUG)
Aida Pharmaceuticals, Inc. (AIDA)
Avivagen Inc. (VIVXF)
Glenmark Life Sciences Limited (GLS.NS)
The CannaBusiness Group, Inc. (CBGI)
Baotou Dongbao Bio-Tech Co.,Ltd (300239.SZ)
Business
MERCK Kommanditgesellschaft auf Aktien (MER.SW), headquartered in Darmstadt, Germany, and founded in 1668 as the world's oldest operating chemical and pharmaceutical company, operates as a leading multinational science and technology group with approximately 60,000 employees across 66 countries; the majority-owned entity (70.3% by the founding Merck family via E. Merck oHG) structures as a KGaA listed on the Frankfurt Stock Exchange and DAX index, encompassing three core sectors: Healthcare, offering oncology products such as Erbitux (cetuximab), Mavenclad for multiple sclerosis, and therapies in fertility, endocrinology, general medicine including diabetes and cardiovascular treatments; Life Science, providing process solutions for biopharma manufacturing with single-use products, science and lab solutions under brands like Sigma-Aldrich, Millipore, SAFC, Supelco, Milli-Q, and Bioreliance for laboratories, quality control, biotech, pharma, diagnostics, academia, food safety, and environmental applications, plus contract development and manufacturing organization (CDMO) services; Electronics, delivering advanced materials for semiconductors, displays, and surface solutions. The company maintains a global presence with around 250 subsidiaries serving diverse markets including pharmaceuticals, biomanufacturing, and high-tech industries. Recent developments include the completed $3.4 billion acquisition of SpringWorks Therapeutics in June 2025, adding FDA-approved therapies Ogsiveo for desmoid tumors and Gomekli for neurofibromatosis type 1 plexiform neurofibromas to bolster its rare oncology portfolio alongside positive European regulatory progress and a licensing deal for pimicotinib from Abbisko Therapeutics; a September 2025 memorandum of understanding with Siemens extending their partnership for AI-driven digital transformation in life sciences using Dotmatics technology; €300 million investment in a new Advanced Research Center in Darmstadt for biotechnological production including antibodies and mRNA by early 2027; and divestment of Surface Solutions to sharpen focus on high-growth sectors.